Pre-treatment estradiol does not predict testosterone response to clomiphene citrate.
Hypogonadism
clomiphene citrate (CC)
estradiol
low testosterone
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
19
5
2020
Statut:
ppublish
Résumé
Clomiphene citrate (CC) is a selective estrogen receptor modulator (SERM) used to stimulate ovulation in women. CC is used off-label in men to increase levels of endogenous testosterone (T) while potentially improving semen parameters by downregulating the inhibitory feedback of estradiol (E) on the male hypothalamus. Our objective was to determine whether pre-treatment E level is associated with greater total testosterone (TT) response to treatment with CC in men with low T. Following IRB approval (The University of Miami IRB No. 20170849), retrospective chart review was performed for all men prescribed CC (25 mg every other day) between January 1, 2015 and December 31, 2018. Age, body mass index (BMI), and prescription date were recorded for all patients. Pre- and post-treatment E, total T (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were recorded for all patients as well. Only men with pretreatment TT <300 ng/dL were included in the analysis in order to focus our study on men with low TT. Univariate linear regression analysis was performed to determinate the percent change in TT following CC treatment (dependent variable) and pre-treatment E and other variables including age, BMI, FSH, and LH (independent variables). A total of 69 men with TT <300 ng/dL received CC 25 mg every other day. Mean age and BMI were 33.3±7.31 years and 35.4±5 kg/m Pre-treatment E level does not appear to predict treatment response with CC in men with low T.
Sections du résumé
BACKGROUND
BACKGROUND
Clomiphene citrate (CC) is a selective estrogen receptor modulator (SERM) used to stimulate ovulation in women. CC is used off-label in men to increase levels of endogenous testosterone (T) while potentially improving semen parameters by downregulating the inhibitory feedback of estradiol (E) on the male hypothalamus. Our objective was to determine whether pre-treatment E level is associated with greater total testosterone (TT) response to treatment with CC in men with low T.
METHODS
METHODS
Following IRB approval (The University of Miami IRB No. 20170849), retrospective chart review was performed for all men prescribed CC (25 mg every other day) between January 1, 2015 and December 31, 2018. Age, body mass index (BMI), and prescription date were recorded for all patients. Pre- and post-treatment E, total T (TT), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were recorded for all patients as well. Only men with pretreatment TT <300 ng/dL were included in the analysis in order to focus our study on men with low TT. Univariate linear regression analysis was performed to determinate the percent change in TT following CC treatment (dependent variable) and pre-treatment E and other variables including age, BMI, FSH, and LH (independent variables).
RESULTS
RESULTS
A total of 69 men with TT <300 ng/dL received CC 25 mg every other day. Mean age and BMI were 33.3±7.31 years and 35.4±5 kg/m
CONCLUSIONS
CONCLUSIONS
Pre-treatment E level does not appear to predict treatment response with CC in men with low T.
Identifiants
pubmed: 32420166
doi: 10.21037/tau.2020.01.30
pii: tau-09-02-609
pmc: PMC7215015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
609-613Informations de copyright
2020 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.01.30). The authors have no conflicts of interest to declare.
Références
Arab J Urol. 2017 Dec 30;16(1):140-147
pubmed: 29713545
Transl Androl Urol. 2018 Jul;7(Suppl 3):S367-S372
pubmed: 30159243
Nature. 1978 May 4;273(5657):57-9
pubmed: 357983
Sex Med Rev. 2019 Apr;7(2):272-276
pubmed: 30522888
J Urol. 2019 Nov;202(5):1029-1035
pubmed: 31216250
Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:104-109
pubmed: 31128532
Curr Urol Rep. 2018 Jun 9;19(8):63
pubmed: 29886559
Eur J Endocrinol. 2018 Jan;178(1):123-130
pubmed: 29066571
Fertil Steril. 2013 Aug;100(2):341-8
pubmed: 23809505
Fertil Steril. 1982 Feb;37(2):168-74
pubmed: 7199484
World J Mens Health. 2019 Jan;37(1):45-54
pubmed: 30350483
Expert Rev Endocrinol Metab. 2019 May;14(3):157-165
pubmed: 31063005
J Sex Med. 2014 Sep;11(9):2302-7
pubmed: 24902614
J Clin Endocrinol Metab. 1974 Jul;39(1):40-5
pubmed: 4600506
J Urol. 2014 Sep;192(3):875-9
pubmed: 24657837
Andrologia. 2019 Jun;51(5):e13257
pubmed: 30779195